RBC Capital Maintains Outperform on Korro Bio, Raises Price Target to $105

Benzinga · 10/21 13:31
RBC Capital analyst Luca Issi maintains Korro Bio (NASDAQ:KRRO) with a Outperform and raises the price target from $95 to $105.